BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32567177)

  • 21. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
    Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
    Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin and trastuzumab regimen induces biventricular failure in mice.
    Milano G; Raucci A; Scopece A; Daniele R; Guerrini U; Sironi L; Cardinale D; Capogrossi MC; Pompilio G
    J Am Soc Echocardiogr; 2014 May; 27(5):568-79. PubMed ID: 24534652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of myocardial changes with and without dexrazoxane using serial magnetic resonance imaging in a pre-clinical mouse model.
    Noel CV; Rainusso N; Robertson M; Romero J; Masand P; Coarfa C; Pautler R
    Cardiooncology; 2021 Jun; 7(1):23. PubMed ID: 34134789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.
    Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS
    J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
    Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.
    Cove-Smith L; Woodhouse N; Hargreaves A; Kirk J; Smith S; Price SA; Galvin M; Betts CJ; Brocklehurst S; Backen A; Radford J; Linton K; Roberts RA; Schmitt M; Dive C; Tugwood JD; Hockings PD; Mellor HR
    Toxicol Sci; 2014 Jul; 140(1):3-15. PubMed ID: 24675088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients.
    Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J
    Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
    Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
    Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
    Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
    BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling.
    Hsu WT; Huang CY; Yen CYT; Cheng AL; Hsieh PCH
    Theranostics; 2018; 8(12):3176-3188. PubMed ID: 29930721
    [No Abstract]   [Full Text] [Related]  

  • 32. Screening for
    Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
    Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity.
    Gupta A; Rohlfsen C; Leppo MK; Chacko VP; Wang Y; Steenbergen C; Weiss RG
    PLoS One; 2013; 8(10):e74675. PubMed ID: 24098344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping.
    Haslbauer JD; Lindner S; Valbuena-Lopez S; Zainal H; Zhou H; D'Angelo T; Pathan F; Arendt CA; Bug G; Serve H; Vogl TJ; Zeiher AM; Carr-White G; Nagel E; Puntmann VO
    Int J Cardiol; 2019 Jan; 275():179-186. PubMed ID: 30360992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity.
    Wang F; Chandra J; Kleinerman ES
    Cancer Med; 2021 Nov; 10(21):7572-7584. PubMed ID: 34523825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
    Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
    Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac Structure-Function MRI in Patients After Heart Transplantation.
    Dolan RS; Rahsepar AA; Blaisdell J; Lin K; Suwa K; Ghafourian K; Wilcox JE; Khan SS; Vorovich EE; Rich JD; Anderson AS; Yancy CW; Collins JD; Markl M; Carr JC
    J Magn Reson Imaging; 2019 Mar; 49(3):678-687. PubMed ID: 30142237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cardioprotective Role of N-Acetyl Cysteine Amide in the Prevention of Doxorubicin and Trastuzumab-Mediated Cardiac Dysfunction.
    Goyal V; Bews H; Cheung D; Premecz S; Mandal S; Shaikh B; Best R; Bhindi R; Chaudhary R; Ravandi A; Thliveris J; Singal PK; Niraula S; Jassal DS
    Can J Cardiol; 2016 Dec; 32(12):1513-1519. PubMed ID: 27650929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.